Business Standard

DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia

Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters

Dr Reddy's
Premium

DRL’s revenues for the third quarter touched Rs 6770 crore, while its gross margins came in at 59.2 percent. The stock was down 1.1 percent on the BSE.

Sohini Das Mumbai
Hyderabad based Dr Reddy’s Laboratories posted a strong net profit growth of 77 per cent year on year to Rs 1,247 crore riding on the back of a 27 per cent rise in revenues largely driven by the North American and Russian markets. The company said its continued focus on improving productivity has also helped boost the profits.

DRL is now bullish on its biosimilars business and hopes to start filing for these products in the US in the coming quarters, and has also finished the phase one clinical trials of tocilizumab, a monoclonal antibody used for the treatment of

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 25 2023 | 6:59 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com